The legal classification of designer opioids is a moving target. Many of these substances are initially legal loopholes, as their specific chemical structures are not yet covered by drug control laws. This necessitates constant updates to legislation and international drug treaties to include new compounds. Regulatory agencies face the challenge of balancing timely legal action with the need for comprehensive evaluation of the substances involved.
